Table 3.

Meta-analysis studies on the efficacy of EGb 761^® in patients with MCI, mild and moderate dementia with or without behavioral deficits.

Meta-Analysis Studies (Inclusion Criteria)	Treatment Groups	Results	References
Patients affected by dementia, associated with psycho-behavioral deficits	EGb 761® (240 mg/die) or placebo	Patients treated with EGb 761® showed benefits on cognitive decline stabilization or slowing down, on ADL and neuro psychiatric deficit for MCI, Alzheimer’s and dementia (with/without neuropsychiatric problems) patients.	[44]
Patients with a diagnosis of AD, VaD, or mixed dementia	EGb 761® (120 mg/die) or EGb 761® (240 mg/die) or placebo	EGb 761® (240 mg/die; best dosage) has been demonstrated efficacy on cognitive functions, including significant neuropsychiatric deficits in patients with dementia.	[15]
Patients with AD or AD + VaD patients	EGb 761® (120 mg/die) or EG b761® (240 mg/die) or placebo	Patients treated with EGb 761® (240 mg/die) showed benefits versus placebo for cognitive deficits, through Syndrom–Kurztest [SKT] analysis.	[104]
Patients with the diagnosis of AD, VaD or mixed dementia with behavioral and psychological symptoms (BPSD)	EGb 761® (240 mg/die) or placebo	EGb 761® ginkgo biloba extract (240 mg/die) improved the patients’ cognitive performance, BPSD, functional abilities and general condition.	[105]
Patients with MCI and dementia (AD, VaD or AD + VaD, mixed dementia)	EGb 761® (240 mg/die) or placebo	EGb 761® showed benefit versus placebo for cognition, behavior and activities of daily living in patients with MCI and dementia.	[106]
Patients with dementia (probable AD, VaD or AD +CVD)	EGb 761® (240 mg/die) or placebo	EGb 761® improved neuro-psychiatric symptoms, in AD, VaD or AD + CVD patients, except for delirium, hallucination and euphoria.	[107]